文献速递消化系统肿瘤

微卫星不稳定结直肠癌辅助治疗的跨试验比较:敢于设想未来场景

Cross-trial comparisons for the adjuvant treatment of MSI colorectal cancer: dare to dream the future scenarios.
PubMed 文献 · Eur J Cancer · 2024-01-19

本文探讨微卫星不稳定(MSI)结直肠癌新辅助免疫检查点抑制剂治疗中纳武利尤单抗联合伊匹木单抗及多塔利单抗带来的前所未有的病理和临床完全缓解率,以及随访第一年0%的复发率,并与新辅助化疗(放疗)11%至28%的复发率比较;作者提醒短期随访下解读需谨慎,数据成熟后的意义尚待观察。

要点

  • MSI结直肠癌新辅助免疫治疗报道了前所未有的完全病理和临床缓解率。
  • 随访第一年观察到的复发率为0%,但短期随访下解读需谨慎。
  • 新辅助化疗(放疗)治疗的MSI结直肠癌复发率为11%至28%。

核心结论

  • 新辅助检查点抑制剂在MSI结直肠癌中取得的显著疗效有潜力革新该领域的治疗格局,但短期随访下的 exceptional 缓解解读需谨慎,未来意义取决于数据随时间成熟。

研究设计与样本

  • 本文为探讨MSI结直肠癌辅助治疗跨试验比较及未来可能场景的论述性稿件。

主要发现

  • 结肠癌中纳武利尤单抗联合伊匹木单抗及直肠癌中多塔利单抗带来了前所未有的完全病理和临床缓解率。
  • 这些缓解进一步由无复发表明,随访第一年观察到的复发率为0%。
  • 与新辅助化疗(放疗)治疗的MSI结直肠癌病例中观察到的11%至28%的较高复发率相比,上述成就的意义更为明显。

局限性

  • 在肿瘤学中解读如此 exceptional 的缓解需谨慎,尤其是在短期随访期内。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The remarkable outcomes achieved with neoadjuvant checkpoint inhibitors for patients diagnosed with MSI colorectal cancer hold the potential to revolutionize the treatment landscape in this context. Specifically, the combination of nivolumab plus ipilimumab in colon cancer and dostarlimab in rectal cancer has led to an unprecedented rate of complete pathological and clinical responses. Notably, these responses have been further substantiated by the absence of relapses, with a 0% relapse rate observed during the first year of follow-up. The significance of these achievements becomes even more apparent when compared to the relatively high relapse rates, ranging from 11% to 28%, observed in MSI colorectal cancer cases treated neoadjuvantly with chemo(radio)therapy. However, it is crucial to exercise caution when interpreting such exceptional responses in oncology, especially within a short follow-up period. The future implications of these findings will depend on how the data mature over time. In this manuscript, we attempt to explore the potential scenarios that may unfold in the near future.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Pastorino A, Catalano F, Zalcberg JR, et al. Cross-trial comparisons for the adjuvant treatment of MSI colorectal cancer: dare to dream the future scenarios. Eur J Cancer. 2024. PMID: 38278008. doi:10.1016/j.ejca.2024.113538

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。